Literature DB >> 9142652

One-way synergistic effect of low superantigen concentrations on lipopolysaccharide-induced cytokine production.

J Luhm1, H Kirchner, L Rink.   

Abstract

Lipopolysaccharides (LPS) of gram-negative bacteria and superantigens of gram-positive bacteria are among the main causes of sepsis and septic shock. Symptoms are initiated primarily by the release of endogenous mediators, especially cytokines. In the last few years, increasing evidence for the clinical relevance of mixed sepsis caused by coinfections with both types of bacteria has been found. Therefore, we developed an in vitro mixed sepsis model investigating the effect of different superantigen doses, in combination with different LPS concentrations, on cytokine production in human PBMCs using ELISA and RT-PCR. Low, in vivo relevant concentrations of the superantigen toxic shock syndrome toxin-1 (TSST-1) synergistically enhance LPS-induced production of interferon-gamma (IFN-gamma) interleukin-1 beta (IL-1 beta), IL-6, and IL-10, but low LPS has no comparable effect. Signal transduction studies with different inhibitors suggest that this one-way synergism is caused by an interaction between the cAMP and the PIP2 signaling pathway. Furthermore, our findings support the idea that this interaction is one important crossover point of signal transduction pathways by LPS and superantigens, which seems to be predominantly regulated by IFN-gamma and PGE-2. The identification of additional crossover points in the genesis of a mixed sepsis and their selective influence could lead to identical treatment of both gram-negative and gram-positive sepsis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142652     DOI: 10.1089/jir.1997.17.229

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  8 in total

1.  Mycobacterium bovis BCG-infected mice are more susceptible to staphylococcal enterotoxin B-mediated toxic shock than uninfected mice despite reduced in vitro splenocyte responses to superantigens.

Authors:  João A Pedras-Vasconcelos; Yvan Chapdelaine; Renu Dudani; Henk van Faassen; Dean K Smith; Subash Sad
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

2.  Systemic inflammatory response syndrome: a new direction?

Authors:  M R Kell; B D Barry; H P Redmond
Journal:  Ir J Med Sci       Date:  2003 Jan-Mar       Impact factor: 1.568

3.  Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release.

Authors:  T Krakauer; B G Stiles
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1.

Authors:  B G Stiles; Y G Campbell; R M Castle; S A Grove
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

5.  The Superantigen Toxic Shock Syndrome Toxin 1 Alters Human Aortic Endothelial Cell Function.

Authors:  Katarina Kulhankova; Kyle J Kinney; Jessica M Stach; Françoise A Gourronc; Isabella M Grumbach; Aloysius J Klingelhutz; Wilmara Salgado-Pabón
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

6.  Toxic Shock Syndrome Toxin 1 Induces Immune Response via the Activation of NLRP3 Inflammasome.

Authors:  Lianci Peng; Jiali Jiang; Tingting Chen; Dongyi Xu; Fengqing Hou; Qingyuan Huang; Yuanyi Peng; Chao Ye; Dong-Liang Hu; Rendong Fang
Journal:  Toxins (Basel)       Date:  2021-01-18       Impact factor: 4.546

Review 7.  Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression.

Authors:  Katarina Kulhankova; Jessica King; Wilmara Salgado-Pabón
Journal:  Immunol Res       Date:  2014-08       Impact factor: 4.505

8.  Beta-(1-->3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio.

Authors:  Juergen Luhm; Ulrich Langenkamp; Jenny Hensel; Christoph Frohn; Joerg M Brand; Holger Hennig; Lothar Rink; Petra Koritke; Nadine Wittkopf; David L Williams; Antje Mueller
Journal:  BMC Immunol       Date:  2006-03-22       Impact factor: 3.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.